Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | SGN-35C |
Synonyms | |
Therapy Description |
SGN-35C is an antibody-drug conjugate (ADC) comprising an antibody targeting CD30 linked to a camptothecin-derived TOP1 inhibitor, which potentially induces cytotoxicity against tumor cells and inhibits tumor growth (Blood (2023) 142 (Supplement 1): 1440). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
SGN-35C | SGN 35C|SGN35C | SGN-35C is an antibody-drug conjugate (ADC) comprising an antibody targeting CD30 linked to a camptothecin-derived TOP1 inhibitor, which potentially induces cytotoxicity against tumor cells and inhibits tumor growth (Blood (2023) 142 (Supplement 1): 1440). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06254495 | Phase I | SGN-35C | A Safety Study of SGN-35C in Adults With Advanced Cancers | Recruiting | USA | ITA | DNK | 0 |